Latest news with #Biegelsen
Business Insider
22-07-2025
- Business
- Business Insider
Wells Fargo Remains a Buy on Dexcom (DXCM)
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom yesterday and set a price target of $98.00. The company's shares closed yesterday at $84.03. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Biegelsen is a 4-star analyst with an average return of 6.1% and a 55.00% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Dexcom, Medtronic, and Abbott Laboratories. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $99.46 average price target, a 18.36% upside from current levels. In a report released on July 16, Mizuho Securities also upgraded the stock to a Buy with a $100.00 price target. The company has a one-year high of $113.28 and a one-year low of $57.52. Currently, Dexcom has an average volume of 3.6M.
Business Insider
29-06-2025
- Business
- Business Insider
Wells Fargo Reaffirms Their Buy Rating on Boston Scientific (BSX)
In a report released on June 26, Larry Biegelsen from Wells Fargo maintained a Buy rating on Boston Scientific (BSX – Research Report), with a price target of $118.00. The company's shares closed last Friday at $106.53. Don't Miss TipRanks' Half Year Sale Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Biegelsen is a 5-star analyst with an average return of 7.1% and a 56.49% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Dexcom, and Medtronic. Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $120.05, representing a 12.69% upside. In a report released on June 27, Bank of America Securities also maintained a Buy rating on the stock with a $115.00 price target. BSX market cap is currently $157.6B and has a P/E ratio of 78.06. Based on the recent corporate insider activity of 122 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year. Last month, Edward Ludwig, a Director at BSX sold 4,000.00 shares for a total of $418,360.00.
